2011 Sep 12;343:d5228. Epub 2018 Jun 29. Increased risk for hyperkalaemia with trimethoprim treatment appears to be related to both higher dosages and underlying renal impairment. Background Trimethoprim therapy can cause hyperkalemia and is often coprescribed with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). 2018 Dec;23(6):233-234. doi: 10.1136/bmjebm-2018-110991. Unable to load your delegates due to an error Hyperkalemia has been reported in 16 to 21 percent of patients hospitalized with the acquired immunodeficiency syndrome (AIDS)1–3.
2018 Oct-Dec;40(4):410-417. doi: 10.1590/2175-8239-JBN-3821. Please enable it to take advantage of the complete set of features! Unable to load your collection due to an error In circumstances where continued treatment with trimethoprim is required, induction of high urinary flow rates with intravenous fluids and a loop diuretic, as well as alkalinisation of the urine, have been shown to block the antikaliuretic effect of trimethoprim on distal nephron cells.
Springer Springer Name must be less than 100 characters Clipboard, Search History, and several other advanced features are temporarily unavailable. The recognition of this disorder of potassium homeostasis prompted the investigation and ultimate description of the mechanism by which trimethoprim causes hyperkalaemia. 2020 Jun;42(3):965-971. doi: 10.1007/s11096-020-01052-x.Takubo M, Tanaka S, Kushimoto M, Ikeda J, Ogawa K, Suzuki Y, Abe M, Ishihara H, Fujishiro M.Antibiotics (Basel).
Prevention of this adverse reaction depends upon recognition of patients at risk of developing hyperkalaemia as well as proper dosage selection of trimethoprim for the patient's prevailing glomerular filtration rate.
Other risk factors for the development of hyperkalemia include renal dysfunction, diabetes, advanced age, and the use of salt substitutes containing potassium chloride or nonsteroidal anti-inflammatory drugs. Cases of hypoglycemia in non-diabetic patients treated with Bactrim are seen rarely, usually occurring after a few days of therapy. /publications/issue/2011/February2011/DrugInteractions-02112 Clarke Drive Suite 100 Cranbury, NJ 08512 P:609-716-7777 F:609-716-9038 1997 Sep-Oct;4(9-10):343-8. doi: 10.1097/00045391-199709000-00010.Crellin E, Mansfield KE, Leyrat C, Nitsch D, Douglas IJ, Root A, Williamson E, Smeeth L, Tomlinson LA.Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, Weir MA, Juurlink DN.BMJ.
Management of hyperkalaemia often mandates discontinuation of the drug, volume repletion with isotonic fluids, and other therapies specific to hyperkalaemia. COVID-19 is an emerging, rapidly evolving situation. Trimethoprim was found to reduce renal potassium excretion through the competitive inhibition of epithelial sodium channels in the distal nephron, in a manner identical to the potassium-sparing diuretic amiloride. It is probable that other disturbances in potassium homeostasis, such as hyopoaldosteronism and treatment with medications that impair renal potassium excretion, are also risk factors for hyperkalaemia with trimethoprim therapy. There are numerous potential causes of hyperkalemia, but they can be broken down into three major categories. doi: 10.2165/00002018-200022030-00006. No such risk was identified with ciprofloxacin, norfloxacin, or nitrofurantoin. doi: 10.2165/00002018-200022030-00006. 2020 Apr 23;9(4):201. doi: 10.3390/antibiotics9040201.Anstrom KJ, Noth I, Flaherty KR, Edwards RH, Albright J, Baucom A, Brooks M, Clark AB, Clausen ES, Durheim MT, Kim DY, Kirchner J, Oldham JM, Snyder LD, Wilson AM, Wisniewski SR, Yow E, Martinez FJ; CleanUP-IPF Study Team.Respir Res. Patients with renal dysfunction, liver disease, malnutrition or those receiving high doses of Bactrim are particularly at risk.
2018 Oct-Dec;40(4):410-417. doi: 10.1590/2175-8239-JBN-3821. Please enable it to take advantage of the complete set of features! Unable to load your collection due to an error In circumstances where continued treatment with trimethoprim is required, induction of high urinary flow rates with intravenous fluids and a loop diuretic, as well as alkalinisation of the urine, have been shown to block the antikaliuretic effect of trimethoprim on distal nephron cells.
Springer Springer Name must be less than 100 characters Clipboard, Search History, and several other advanced features are temporarily unavailable. The recognition of this disorder of potassium homeostasis prompted the investigation and ultimate description of the mechanism by which trimethoprim causes hyperkalaemia. 2020 Jun;42(3):965-971. doi: 10.1007/s11096-020-01052-x.Takubo M, Tanaka S, Kushimoto M, Ikeda J, Ogawa K, Suzuki Y, Abe M, Ishihara H, Fujishiro M.Antibiotics (Basel).
Prevention of this adverse reaction depends upon recognition of patients at risk of developing hyperkalaemia as well as proper dosage selection of trimethoprim for the patient's prevailing glomerular filtration rate.
Other risk factors for the development of hyperkalemia include renal dysfunction, diabetes, advanced age, and the use of salt substitutes containing potassium chloride or nonsteroidal anti-inflammatory drugs. Cases of hypoglycemia in non-diabetic patients treated with Bactrim are seen rarely, usually occurring after a few days of therapy. /publications/issue/2011/February2011/DrugInteractions-02112 Clarke Drive Suite 100 Cranbury, NJ 08512 P:609-716-7777 F:609-716-9038 1997 Sep-Oct;4(9-10):343-8. doi: 10.1097/00045391-199709000-00010.Crellin E, Mansfield KE, Leyrat C, Nitsch D, Douglas IJ, Root A, Williamson E, Smeeth L, Tomlinson LA.Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, Weir MA, Juurlink DN.BMJ.
Management of hyperkalaemia often mandates discontinuation of the drug, volume repletion with isotonic fluids, and other therapies specific to hyperkalaemia. COVID-19 is an emerging, rapidly evolving situation. Trimethoprim was found to reduce renal potassium excretion through the competitive inhibition of epithelial sodium channels in the distal nephron, in a manner identical to the potassium-sparing diuretic amiloride. It is probable that other disturbances in potassium homeostasis, such as hyopoaldosteronism and treatment with medications that impair renal potassium excretion, are also risk factors for hyperkalaemia with trimethoprim therapy. There are numerous potential causes of hyperkalemia, but they can be broken down into three major categories. doi: 10.2165/00002018-200022030-00006. No such risk was identified with ciprofloxacin, norfloxacin, or nitrofurantoin. doi: 10.2165/00002018-200022030-00006. 2020 Apr 23;9(4):201. doi: 10.3390/antibiotics9040201.Anstrom KJ, Noth I, Flaherty KR, Edwards RH, Albright J, Baucom A, Brooks M, Clark AB, Clausen ES, Durheim MT, Kim DY, Kirchner J, Oldham JM, Snyder LD, Wilson AM, Wisniewski SR, Yow E, Martinez FJ; CleanUP-IPF Study Team.Respir Res. Patients with renal dysfunction, liver disease, malnutrition or those receiving high doses of Bactrim are particularly at risk.